Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2008-03-18
Morris, Patricia L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S236000
Reexamination Certificate
active
11054226
ABSTRACT:
Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: n is 2, 3, or 4 and W is CH2, CH(OH), C(O) or O; R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, heterocycloalkyl, aryl-alkyl, heteroaryl-alkyl, cycloalkyl-alkyl, or t-butyl; R2 is H, alkyl, haloalkyl or phenyl; Y is an unsubstituted or substituted thiophen-2,5-diyl or phenylene; R3 is alkyl or haloalkyl; R4 is a substituted or unsubstituted phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, pyridyl or benzo[1,3]dioxol-5-yl group; and R5 is H, alkyl, or aminoalkyl; are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.
REFERENCES:
patent: 5089514 (1992-02-01), Hulin
patent: 5232945 (1993-08-01), Hulin
patent: 5306726 (1994-04-01), Hulin
patent: 5902726 (1999-05-01), Kliewer et al.
patent: 5994554 (1999-11-01), Kliewer et al.
patent: 7176224 (2007-02-01), Ardecky et al.
patent: 0 930 229 (1999-07-01), None
patent: 2 359 082 (2001-08-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/31907 (1997-09-01), None
patent: WO 99/46232 (1999-09-01), None
patent: WO 01/16120 (2001-03-01), None
patent: WO 02/16332 (2002-02-01), None
patent: WO 02/18355 (2002-03-01), None
Collins et al., N-(2-Benzoylphenyl), etc., J. Med. Chem. 1988, 41, 5037-5054.
Sarges, R., et al.: “Glucose Transport-Enhancing and Hypoglycemic Activity of 2-Methyl-2-Phenoxy-3-Phenylpropanoic Acids”; Journal of Medicinal Chemistry, vol. 39, No. 24, Nov. 22, 1996, pp. 4783-4803.
Cobb, J. E., et al.: “N-(2-Benzoylphenyl)-L-Tyrosine PPARGamma Agonists. 3. Structure-Activity Relationship and Optimization of the N-Aryl Substituent”; Journal of Medicinal Chemistry, vol. 41, No. 25, Dec. 3, 1998, pp. 5055-5069.
Bright, S.W., et. al.: “Competitive Particle Concentration Fluorescence Immunoassays for Measuring Anti-Diabetic Drug Levels in Mouse Plasma”; Journal of Immunological Methods, vol. 207, No. 1, Aug. 22, 1997, pp. 23-31.
Brooks, D., et al.: “Design and Synthesis of 2-methyl-2-{4-'2-'5-methyl-2-aryloxazol-4-yl)oxylphenoxy}propionic acids: A New Class of Dual PPARAlpha/Gamma Agonists”; Journal of Medicinal Chemistry, vol. 44, No. 13, June 21, 2001, pp. 2061-2064.
Shinkai, H. et al.: “Isoxazolidine-3,5-dione and Noncyclic 1,3-dicarbonyl Compounds as Hypoglycemic Agents”; Journal of Medicinal Chemistry vol. 41, No. 11, May 21, 1998, pp. 1927-1933.
Murugesan, N., et al.: “Biphenylsulfonamide Endothelin Receptor Antogonists 2. Discovery of 4′-oxazoly-lbiphenylsulfonamides as a New Class of Poent, Highly Selective ET(A)Antagonists”; Journal of Medicinal Chemistry, vol. 43, No. 16, Aug. 10, 2000, pp. 3111-3117.
Malamas, M.S., et al.: “Azole Phenoxy Hydroxyureas as Selective and Orally Active Inhibitors fo 5-Lipoxygenase”; Journal of Medicinal Chemistry, vol. 39, No. 1, Jan. 5, 1996, pp. 237-245.
Merguro, K., et al.: “Studies on Antidiabetic Agents. VII. Synthesis and Hypoglycemic Activity fo 4-Oxazoleacetic Acid Derivatives”; Chemical & Pharmaceutical Bulletin, vol. 34, No. 7, 1986, pp. 2840-2851.
Brooks Dawn Alisa
Godfrey Alexander Glenn
Jones Sarah Beth
McCarthy James Ray
Rito Christopher John
Eli Lilly and Company
Jang Soonhee
Morris Patricia L.
Vorndran-Jones MaCharri
LandOfFree
Peroxisome proliferator activated receptor agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peroxisome proliferator activated receptor agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peroxisome proliferator activated receptor agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3931903